Patents by Inventor Joergen Johnsson
Joergen Johnsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10583146Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.Type: GrantFiled: April 17, 2014Date of Patent: March 10, 2020Assignee: SHIRE VIROPHARMA INCORPORATEDInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Patent number: 10413555Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: GrantFiled: November 24, 2015Date of Patent: September 17, 2019Assignee: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Publication number: 20190216822Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (OHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skill were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHKA, TWAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (MNP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Patent number: 10285997Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: GrantFiled: November 24, 2015Date of Patent: May 14, 2019Assignee: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Patent number: 9925139Abstract: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid.Type: GrantFiled: April 21, 2005Date of Patent: March 27, 2018Assignee: ACUCORT ABInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Publication number: 20170319598Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.Type: ApplicationFiled: November 24, 2015Publication date: November 9, 2017Applicant: TROPHEA DEVELOPMENT ABInventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
-
Patent number: 9315444Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).Type: GrantFiled: June 20, 2014Date of Patent: April 19, 2016Assignee: Laccure ABInventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Publication number: 20150025142Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).Type: ApplicationFiled: June 20, 2014Publication date: January 22, 2015Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Patent number: 8912232Abstract: The invention relates to an oligomeric lactic acid composition comprising one or more oligomers of lactic acid or a pharmaceutical composition comprising an oligomeric lactic acid composition for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment.Type: GrantFiled: March 28, 2013Date of Patent: December 16, 2014Assignee: Laccure ABInventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Publication number: 20140242167Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder.Type: ApplicationFiled: April 17, 2014Publication date: August 28, 2014Applicant: DuoCort Pharma ABInventors: Stanko SKRTIC, Jörgen JOHNSSON, Hans LENNERNÄS, Thomas HEDNER, Gudmundur JOHANNSSON
-
Publication number: 20130317104Abstract: The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).Type: ApplicationFiled: March 28, 2013Publication date: November 28, 2013Inventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Patent number: 8425937Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents.Type: GrantFiled: April 21, 2005Date of Patent: April 23, 2013Assignee: DuoCort Pharma ABInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Patent number: 8425894Abstract: Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).Type: GrantFiled: March 28, 2008Date of Patent: April 23, 2013Assignee: Laccure ABInventors: Greg Batcheller, Thomas Hedner, Joergen Johnsson, Werner Schubert, Christer Sjoegren, Olov Sterner, Malgorzat Sznitowska
-
Publication number: 20120183610Abstract: The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects.Type: ApplicationFiled: April 7, 2010Publication date: July 19, 2012Inventors: Hans Lennernäs, Jörgen Johnsson, Thomas Hedner, Gudmundur Johannsson, Stanko Skrtic
-
Publication number: 20100062981Abstract: The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve.Type: ApplicationFiled: January 30, 2008Publication date: March 11, 2010Inventors: Anders Jeppsson, Stanko Skrtic, Lennart Bruce, Jörgen Johnsson, Thomas Hedner